Therapy and clinical trials in frontotemporal dementia: past, present, and future

Frontotemporal dementia (FTD) is a common form of dementia with heterogeneous clinical presentations and distinct clinical syndromes. This article will review currently available therapies for FTD, its related disorders and their clinical evidence. It will also discuss recent advancements in FTD pathophysiology, treatment development, biomarker advancement and their relation to recently completed or currently ongoing clinical trials as well as future implications.

[1]  H. Arai,et al.  18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[2]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[3]  D. J. Brooks,et al.  Tau imaging in neurodegenerative diseases , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  Keith A. Johnson,et al.  Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.

[5]  E. Gómez-Tortosa,et al.  Behavioral Evolution of Progressive Semantic Aphasia in Comparison with Nonfluent Aphasia , 2015, Dementia and Geriatric Cognitive Disorders.

[6]  Cassandra J. Anor,et al.  Mutation analysis of C9orf72 in patients with corticobasal syndrome , 2015, Neurobiology of Aging.

[7]  L. Petrucelli,et al.  Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers , 2015, Acta Neuropathologica.

[8]  P. Wong,et al.  Susceptibility-weighted MRI in mild traumatic brain injury , 2015, Neurology.

[9]  N. Krogan,et al.  Critical Role of Acetylation in Tau-Mediated Neurodegeneration and Cognitive Deficits , 2015, Nature Medicine.

[10]  Donna C. Tippett,et al.  Treatment of Primary Progressive Aphasia , 2015, Current Treatment Options in Neurology.

[11]  N. Pearce,et al.  Neurofilament light chain , 2015, Neurology.

[12]  D. Neary,et al.  Cognitive–behavioural features of progressive supranuclear palsy syndrome overlap with frontotemporal dementia , 2015, Journal of Neurology.

[13]  Keith A. Johnson,et al.  Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging , 2015, Neuropathology and applied neurobiology.

[14]  M. Borrie,et al.  Oxytocin for frontotemporal dementia , 2015, Neurology.

[15]  J. Trojanowski,et al.  Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease. , 2014, Bioorganic & medicinal chemistry.

[16]  L. Collin,et al.  Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. , 2014, Brain : a journal of neurology.

[17]  Bruce H. Morimoto,et al.  Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial , 2014, The Lancet Neurology.

[18]  M. Diamond,et al.  Prion-like Properties of Tau Protein: The Importance of Extracellular Tau as a Therapeutic Target* , 2014, The Journal of Biological Chemistry.

[19]  H. Huppertz,et al.  Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial , 2014, Movement disorders : official journal of the Movement Disorder Society.

[20]  E. Tolosa,et al.  A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy , 2014, Movement disorders : official journal of the Movement Disorder Society.

[21]  U. Sengupta,et al.  Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles , 2014, The Journal of Neuroscience.

[22]  M. Muiesan,et al.  Results from a pilot study on amiodarone administration in monogenic frontotemporal dementia with granulin mutation , 2014, Neurological Sciences.

[23]  Chadwick M. Hales,et al.  Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP , 2013, Neurology.

[24]  B. Franke,et al.  Dissociable Effects of Dopamine and Serotonin on Reversal Learning , 2013, Neuron.

[25]  Nipun A. Mistry,et al.  RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention , 2013, Neuron.

[26]  Gene W. Yeo,et al.  Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration , 2013, Proceedings of the National Academy of Sciences.

[27]  L. Petrucelli,et al.  Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion , 2013, Science Translational Medicine.

[28]  F. van Leuven,et al.  Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy , 2013, PloS one.

[29]  Bruno Vellas,et al.  Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force , 2013, Alzheimer's & Dementia.

[30]  D. Arciniegas,et al.  Donepezil-induced confusional state in a patient with autopsy-proven behavioral-variant frontotemporal dementia. , 2013, The Journal of neuropsychiatry and clinical neurosciences.

[31]  B. Ghetti,et al.  Brain homogenates from human tauopathies induce tau inclusions in mouse brain , 2013, Proceedings of the National Academy of Sciences.

[32]  A. Pestronk,et al.  An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study , 2013, The Lancet Neurology.

[33]  P. Davies,et al.  Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity , 2013, PloS one.

[34]  Takemi Kimura,et al.  Pilot study of pharmacological treatment for frontotemporal dementia: Risk of donepezil treatment for behavioral and psychological symptoms , 2013, Geriatrics & gerontology international.

[35]  K. Kortte,et al.  Behavioural interventions for enhancing life participation in behavioural variant frontotemporal dementia and primary progressive aphasia , 2013, International review of psychiatry.

[36]  D. Geschwind,et al.  TDP-43 frontotemporal lobar degeneration and autoimmune disease , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[37]  N. Tsuno,et al.  Managing abnormal eating behaviours in frontotemporal lobar degeneration patients with topiramate , 2013, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.

[38]  Robert V Farese,et al.  The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier) , 2013, Alzheimer's & Dementia.

[39]  Kevin F. Bieniek,et al.  Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS , 2013, Neuron.

[40]  Murray Grossman,et al.  Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet Neurology.

[41]  Mark Hallett,et al.  Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.

[42]  R. Reeves,et al.  Aripiprazole for sexually inappropriate vocalizations in frontotemporal dementia. , 2012, Journal of clinical psychopharmacology.

[43]  A. Boxer,et al.  Treatment implications of C9ORF72 , 2012, Alzheimer's Research & Therapy.

[44]  N. Herrmann,et al.  Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. , 2012, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[45]  T. Cooper,et al.  RNA-binding proteins in microsatellite expansion disorders: Mediators of RNA toxicity , 2012, Brain Research.

[46]  C. Jack,et al.  Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials. , 2012, Parkinsonism & related disorders.

[47]  D. Neary,et al.  Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. , 2012, Brain : a journal of neurology.

[48]  J. Stewart,et al.  Treatment of indiscriminate, inappropriate sexual behavior in frontotemporal dementia with carbamazepine. , 2012, Journal of clinical psychopharmacology.

[49]  David Heckerman,et al.  A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.

[50]  D. Geschwind,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[51]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[52]  P. Davies,et al.  Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models , 2011, The Journal of Biological Chemistry.

[53]  J. Trojanowski,et al.  Clinicopathological correlations in corticobasal degeneration , 2011, Annals of neurology.

[54]  E. Sigurdsson,et al.  Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain , 2011, Journal of neurochemistry.

[55]  Zhinan Yin,et al.  The Growth Factor Progranulin Binds to TNF Receptors and Is Therapeutic Against Inflammatory Arthritis in Mice , 2011, Science.

[56]  P. Nestor.  Reversal of abnormal eating and drinking behaviour in a frontotemporal lobar degeneration patient using low-dose topiramate , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[57]  Robert V Farese,et al.  Suberoylanilide Hydroxamic Acid (Vorinostat) Up-regulates Progranulin Transcription , 2011, The Journal of Biological Chemistry.

[58]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[59]  K. Sleegers,et al.  Rescue of Progranulin Deficiency Associated with Frontotemporal Lobar Degeneration by Alkalizing Reagents and Inhibition of Vacuolar ATPase , 2011, The Journal of Neuroscience.

[60]  E. Yaksi,et al.  Electrical Coupling between Olfactory Glomeruli , 2010, Neuron.

[61]  A. Lees,et al.  Does corticobasal degeneration exist? A clinicopathological re-evaluation. , 2010, Brain : a journal of neurology.

[62]  B. Boeve,et al.  Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[63]  D. Berg,et al.  Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis , 2010, Alzheimer's & Dementia.

[64]  E. Ross,et al.  Behavioural abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[65]  J. Neuhaus,et al.  An Open-label Study of Memantine Treatment in 3 Subtypes of Frontotemporal Lobar Degeneration , 2009, Alzheimer disease and associated disorders.

[66]  K. Sleegers,et al.  Serum biomarker for progranulin‐associated frontotemporal lobar degeneration , 2009, Annals of neurology.

[67]  R. Petersen,et al.  Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members , 2009, Brain : a journal of neurology.

[68]  J. Grafman,et al.  Stimulant treatment of frontotemporal dementia in 8 patients. , 2008, The Journal of clinical psychiatry.

[69]  Nathaniel Mercaldo,et al.  Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. , 2008, Brain : a journal of neurology.

[70]  G. Binetti,et al.  Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration , 2008, Neurology.

[71]  Peter Heutink,et al.  Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia , 2008, The Lancet Neurology.

[72]  Leonardo Franklin Fontenelle,et al.  Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report. , 2008, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[73]  A. Kertesz,et al.  Galantamine in Frontotemporal Dementia and Primary Progressive Aphasia , 2008, Dementia and Geriatric Cognitive Disorders.

[74]  J. Merrilees.  A Model for Management of Behavioral Symptoms in Frontotemporal Lobar Degeneration , 2007, Alzheimer disease and associated disorders.

[75]  Ayodeji A. Asuni,et al.  Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements , 2007, The Journal of Neuroscience.

[76]  L. Golbe,et al.  A clinical rating scale for progressive supranuclear palsy. , 2007, Brain : a journal of neurology.

[77]  J. Trojanowski,et al.  Cognitive and motor assessment in autopsy-proven corticobasal degeneration , 2007, Neurology.

[78]  M. Swanberg.  Memantine for Behavioral Disturbances in Frontotemporal Dementia: A Case Series , 2007, Alzheimer disease and associated disorders.

[79]  Matthias J. Müller,et al.  Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism , 2007, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[80]  S H Appel,et al.  Prevalence and patterns of cognitive impairment in sporadic ALS , 2005, Neurology.

[81]  J. Shapira,et al.  Stereotypical movements and frontotemporal dementia , 2005, Movement disorders : official journal of the Movement Disorder Society.

[82]  B. L. Miller,et al.  The natural history of temporal variant frontotemporal dementia , 2005, Neurology.

[83]  Daniela Perani,et al.  Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration , 2005, Annals of neurology.

[84]  K. Blennow,et al.  Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[85]  F. Pasquier,et al.  Frontotemporal Dementia: A Randomised, Controlled Trial with Trazodone , 2004, Dementia and Geriatric Cognitive Disorders.

[86]  B. Sahakian,et al.  Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial , 2004, Psychopharmacology.

[87]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[88]  A. Bava,et al.  Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: A 24-month follow-up of 68 patients , 2003, American journal of Alzheimer's disease and other dementias.

[89]  Nick C Fox,et al.  Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration , 2003, International journal of geriatric psychiatry.

[90]  A. Bava,et al.  Frontotemporal Dementia: Paroxetine as a Possible Treatment of Behavior Symptoms , 2002, European Neurology.

[91]  C. Robinson,et al.  Progressive supranuclear palsy diagnosis and confounding features: Report on 16 autopsied cases , 2002, Movement disorders : official journal of the Movement Disorder Society.

[92]  M. Mendez,et al.  Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration , 2002, American journal of Alzheimer's disease and other dementias.

[93]  J. Trojanowski,et al.  Sporadic Pick's disease: A tauopathy characterized by a spectrum of pathological τ isoforms in gray and white matter , 2002, Annals of neurology.

[94]  D. Dickson,et al.  Morphological and Biochemical Correlations of Abnormal Tau Filaments in Progressive Supranuclear Palsy , 2002, Journal of neuropathology and experimental neurology.

[95]  M. Hallett,et al.  Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy , 2001, Neurology.

[96]  H. P. Schmitt,et al.  Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation , 2001, Acta Neuropathologica.

[97]  C. Colosimo,et al.  Donepezil in the treatment of progressive supranuclear palsy , 2001, Acta neurologica Scandinavica.

[98]  R. Curtis,et al.  Case of pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. , 2000, Journal of clinical psychopharmacology.

[99]  A. Delacourte,et al.  Comparative Biochemistry of Tau in Progressive Supranuclear Palsy, Corticobasal Degeneration, FTDP‐17 and Pick's Disease , 1999, Brain pathology.

[100]  P. Francis,et al.  Neurochemical Features of Frontotemporal Dementia , 1999, Dementia and Geriatric Cognitive Disorders.

[101]  J. Hodges,et al.  Frontotemporal dementia , 1999, Neurology.

[102]  K. Jellinger,et al.  Pharmacological therapy in progressive supranuclear palsy. , 1998, Archives of neurology.

[103]  R. Vejsada,et al.  Persephin, a Novel Neurotrophic Factor Related to GDNF and Neurturin , 1998, Neuron.

[104]  J. Swartz,et al.  Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. , 1997, The Journal of clinical psychiatry.

[105]  M. Roth,et al.  Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[106]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[107]  C. Jahr,et al.  β-Adrenergic Regulation of Synaptic NMDA Receptors by cAMP-Dependent Protein Kinase , 1996, Neuron.

[108]  D. Dickson,et al.  Neuropathologic Overlap of Progressive Supranuclear Palsy, Pick's Disease and Corticobasal Degeneration , 1996, Journal of neuropathology and experimental neurology.

[109]  K. Kosik,et al.  Structure and novel exons of the human tau gene. , 1992, Biochemistry.

[110]  A. Hyman,et al.  Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. , 1992, Molecular biology of the cell.

[111]  M. Calvani,et al.  Clues to the Mechanism of Action of Acetyl-L-Carnitine in the Central Nervous System , 1991 .

[112]  T. Yokota,et al.  Serum antibodies to HTLV‐I in autonomic failure with multiple system atrophy , 1990, Annals of neurology.

[113]  F. Clementi,et al.  Cellular immune response against acetylcholine receptor in myasthenia gravis , 1979, Neurology.

[114]  G. Edsall.  PASSIVE IMMUNIZATION. , 1963, Pediatrics.

[115]  R. Staff,et al.  Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.

[116]  J. Kramer,et al.  Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. , 2014, Annals of neurology.

[117]  U. Sengupta,et al.  Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. , 2014, Journal of Alzheimer's disease : JAD.

[118]  M. Walterfang,et al.  Topiramate for Abnormal Eating Behaviour in Frontotemporal Dementia , 2013, Behavioural neurology.

[119]  C. Volteau,et al.  Memantine in behavioral variant frontotemporal dementia: negative results. , 2011, Journal of Alzheimer's disease : JAD.

[120]  R. Panush.  The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice , 2011 .

[121]  M. Freedman,et al.  Frontotemporal dementia and pharmacologic interventions. , 2010, The Journal of neuropsychiatry and clinical neurosciences.

[122]  M. Mendez,et al.  Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. , 2007, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[123]  M. Riepe,et al.  Memantine in Moderate-to-severe Alzheimer's Disease , 2006 .

[124]  A. Bava,et al.  Rivastigmine in Frontotemporal Dementia , 2004, Drugs & aging.

[125]  J. Trojanowski,et al.  Tau and axonopathy in neurodegenerative disorders , 2002, NeuroMolecular Medicine.

[126]  S. Ringel,et al.  Observations on the efficacy of L-dopa in progressive supranuclear palsy. , 1971, European neurology.